{
    "organizations": [],
    "uuid": "7d2b8b3462f872b105a4dd9ec7f9279f918a31f0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ipsen-and-exelixis-announce-phase/brief-ipsen-and-exelixis-announce-phase-3-trial-results-of-cabozantinib-showing-benefit-in-hepatocellular-carcinoma-patients-idUSFWN1PB1C0",
    "ord_in_thread": 0,
    "title": "BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - IPSEN SA:\n* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA\n* IN CELESTIAL, CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT VERSUS PLACEBO IN OVERALL SURVIVAL\n* MEDIAN OS WAS 10.2 MONTHS WITH CABOZANTINIB VERSUS 8.0 MONTHS WITH PLACEBO Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-17T06:06:00.000+02:00",
    "crawled": "2018-01-17T19:45:03.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "ipsen",
        "sa",
        "exelixis",
        "ipsen",
        "announce",
        "phase",
        "trial",
        "result",
        "cabozantinib",
        "demonstrating",
        "significant",
        "overall",
        "survival",
        "benefit",
        "patient",
        "previously",
        "treated",
        "advanced",
        "hepatocellular",
        "carcinoma",
        "celestial",
        "cabozantinib",
        "provided",
        "statistically",
        "significant",
        "clinically",
        "meaningful",
        "improvement",
        "versus",
        "placebo",
        "overall",
        "survival",
        "median",
        "o",
        "month",
        "cabozantinib",
        "versus",
        "month",
        "placebo",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}